AnGes, Inc. Stock

Equities

4563

JP3127700007

Biotechnology & Medical Research

Delayed Japan Exchange 12:40:00 2024-04-30 am EDT 5-day change 1st Jan Change
49 JPY 0.00% Intraday chart for AnGes, Inc. 0.00% -31.94%
Sales 2022 67M 427K Sales 2023 152M 969K Capitalization 14.23B 90.75M
Net income 2022 -14.71B -93.85M Net income 2023 -7.44B -47.43M EV / Sales 2022 165 x
Net cash position 2022 9.88B 63.02M Net cash position 2023 3.8B 24.23M EV / Sales 2023 68.6 x
P/E ratio 2022
-1.29 x
P/E ratio 2023
-1.83 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 96.87%
More Fundamentals * Assessed data
Dynamic Chart
Current month-25.76%
1 month-23.44%
3 months-31.94%
6 months-42.35%
Current year-31.94%
More quotes
1 week
49.00
Extreme 49
51.00
1 month
49.00
Extreme 49
66.00
Current year
49.00
Extreme 49
92.00
1 year
49.00
Extreme 49
143.00
3 years
49.00
Extreme 49
1 060.00
5 years
49.00
Extreme 49
2 492.00
10 years
49.00
Extreme 49
2 492.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 54 12-09-30
President 73 01-04-30
Chief Tech/Sci/R&D Officer 67 19-01-31
Members of the board TitleAgeSince
President 73 01-04-30
Director/Board Member 73 18-03-28
Director/Board Member 73 12-02-29
More insiders
Date Price Change Volume
24-04-30 49 0.00% 521 500
24-04-26 49 0.00% 530,600
24-04-25 49 0.00% 847,400
24-04-24 49 0.00% 515,400
24-04-23 49 -2.00% 1,598,600

Delayed Quote Japan Exchange, April 30, 2024 at 12:40 am EDT

More quotes
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
Calendar
More about the company